Alphyn Biologics Reports Positive Pediatric Results from Phase 2a Atopic Dermatitis Trial NEWS PROVIDED BY Alphyn Biologics May 04, 2023, 07:30 ET Trial meets all primary and secondary endpoints across pediatric population ages 2 and older ANNAPOLIS, Md. and MALAGA, Spain, May 4, 2023 /PRNewswire/ — Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target…
Poster Presentation: Phase 2a Trial of AB-101a for Mild-to-Moderate Atopic Dermatitis, Pediatric Patients NEWS PROVIDED BY Alphyn Biologics May 4, 2023, 07:25 ET CONTACTS Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687 Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195
Alphyn Biologics Presents Pediatric Data from Atopic Dermatitis Trial at European Society for Pediatric Dermatology Congress NEWS PROVIDED BY Alphyn Biologics Apr 27, 2023, 07:30 ET ANNAPOLIS, Md., April 27, 2023 /PRNewswire/ — Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, will present for the first time new pediatric data from its Phase…
VIDEO: Alphyn Biologics’ atopic dermatitis candidate shows positive early results NEWS PROVIDED BY Alphyn Biologics Mar 21, 2023 In this Healio video exclusive from the American Academy of Dermatology Annual Meeting, Neal Koller, founder and CEO of Alphyn Biologics, discusses the clinical-stage company’s drug pipeline. View the video here. CONTACTS Corporate: Neal Koller…
Empowered Patient Podcast: Treating Atopic Dermatitis Using Therapeutic Drug Containing Multiple Bioactive Compounds with Neal Koller Alphyn Biologics NEWS PROVIDED BY Alphyn Biologics Feb 27, 2023 Neal Koller, CEO of Alphyn Biologics, discusses their first topical drug which treats both atopic dermatitis and atopic dermatitis with secondary infection. Listen to the podcast here. CONTACTS…
Alphyn Biologics Reports Positive Results from First Cohort of Phase 2a Trial of Mild-to-Moderate Atopic Dermatitis Treatment NEWS PROVIDED BY Alphyn Biologics Jan 4, 2023, 07:30 ET ANNAPOLIS, Md., Jan. 4, 2023 /PRNewswire/ — Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced today positive results from the first cohort of its Phase…
Alphyn Biologics Completes First Cohort of Phase2a Clinical Trial of Topical Therapeutic for Mild-to-Moderate Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics Nov 15, 2022, 07:30 ET ANNAPOLIS, Md., Nov. 15, 2022 /PRNewswire/ — Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced today that it has completed the first cohort of its Phase2a…
Alphyn Biologics Announces Enrollment Passes Halfway Point in Phase2a Clinical Trial of Mild-to-Moderate Atopic Dermatitis Treatment NEWS PROVIDED BY Alphyn Biologics Oct 18, 2022, 07:30 ET Study evaluates AB-101a for patients with and without concurrent bacterial infection ANNAPOLIS, Md., Oct. 18, 2022 /PRNewswire/ — Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced…
Alphyn Biologics Closes $3.3 Million Series A Financing to Advance Breakthrough Atopic Dermatitis Treatment Over-subscribed round to support Phase2a clinical trial in atopic dermatitis ANNAPOLIS, MD, September 15, 2022 – Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced today that it is has closed a Series A financing round of approximately $3.3…